Overview

Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This is a phase 1b, open-Label study of sorafenib with BIIB022 in subjects with advanced hepatocellular carcinoma.
Phase:
Phase 1
Details
Lead Sponsor:
Biogen
Treatments:
Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulins
Liver Extracts
Niacinamide
Sorafenib